MX2017001569A - Formulaciones de suspención oral en polvo de agentes antibacterianos. - Google Patents

Formulaciones de suspención oral en polvo de agentes antibacterianos.

Info

Publication number
MX2017001569A
MX2017001569A MX2017001569A MX2017001569A MX2017001569A MX 2017001569 A MX2017001569 A MX 2017001569A MX 2017001569 A MX2017001569 A MX 2017001569A MX 2017001569 A MX2017001569 A MX 2017001569A MX 2017001569 A MX2017001569 A MX 2017001569A
Authority
MX
Mexico
Prior art keywords
oral suspension
formulations
suspension formulations
bacterial infections
antibacterial agents
Prior art date
Application number
MX2017001569A
Other languages
English (en)
Inventor
Fernandes Prabhavathi
Majuru Shingai
Eugene Pereira David
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Publication of MX2017001569A publication Critical patent/MX2017001569A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

En el presente documento se describen formulaciones de suspensión oral en polvo de compuestos antibacterianos. Además, se describen polvos reconstituibles de composiciones antibacterianas y sus formulaciones en suspensión oral. Durante muchos años, ha habido una gran necesidad de una formulación de suspensión oral para tratar infecciones bacterianas. Está bien entendido que las indicaciones pediátricas se basan en tales formulaciones para el tratamiento eficaz de infecciones bacterianas en niños y bebes. Además, otros patinetes, como pacientes geriátricos, que no pueden o no tragaran tabletas o capsulas, especialmente cuando están por encima de ciertos límites dimensionales, también confían en tales formulaciones para el tratamiento eficaz de infecciones bacterianas.
MX2017001569A 2014-08-05 2015-08-05 Formulaciones de suspención oral en polvo de agentes antibacterianos. MX2017001569A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462033601P 2014-08-05 2014-08-05
US201562173609P 2015-06-10 2015-06-10
PCT/US2015/043774 WO2016022658A1 (en) 2014-08-05 2015-08-05 Powder oral suspension formulations of antibacterial agents

Publications (1)

Publication Number Publication Date
MX2017001569A true MX2017001569A (es) 2017-08-07

Family

ID=55264484

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001569A MX2017001569A (es) 2014-08-05 2015-08-05 Formulaciones de suspención oral en polvo de agentes antibacterianos.

Country Status (14)

Country Link
US (2) US20170224664A1 (es)
EP (1) EP3185864A4 (es)
JP (1) JP2017523975A (es)
KR (1) KR20170039689A (es)
CN (1) CN106604729A (es)
AU (1) AU2015301154A1 (es)
BR (1) BR112017002335A2 (es)
CA (1) CA2957034A1 (es)
IL (1) IL250349A0 (es)
MX (1) MX2017001569A (es)
RU (1) RU2017104163A (es)
SG (1) SG11201700827RA (es)
WO (1) WO2016022658A1 (es)
ZA (1) ZA201701487B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5698979B2 (ja) 2007-10-25 2015-04-08 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド系抗菌剤の調製プロセス
JP5602748B2 (ja) 2008-10-24 2014-10-08 センプラ ファーマシューティカルズ，インコーポレイテッド トリアゾール含有マクロライドを用いた生体防御
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
US10188674B2 (en) 2012-03-27 2019-01-29 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
JP6426696B2 (ja) 2013-03-14 2018-11-21 センプラ ファーマシューティカルズ，インコーポレイテッド 呼吸器疾患の治療のための方法および製剤
US10163241B2 (en) * 2016-12-09 2018-12-25 Microsoft Technology Licensing, Llc Automatic generation of fundus drawings
JP7089855B2 (ja) * 2017-10-02 2022-06-23 三栄源エフ・エフ・アイ株式会社 苦味マスキング組成物
JP7546138B2 (ja) 2021-12-21 2024-09-05 上海奥全生物医葯科技有限公司 固形剤形を水に分散させて懸濁液を形成する方法、懸濁液および固体剤形を投与する方法
CN114432241B (zh) * 2021-12-21 2023-07-14 上海奥全生物医药科技有限公司 一种快速分散的助悬组合物、制备方法及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2821747B1 (fr) * 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Suspension de telithromycine a gout masque
FR2826274B1 (fr) * 2001-06-21 2003-09-26 Aventis Pharma Sa Formulation pharmaceutique au gout masque et son procede de preparation
US20040013737A1 (en) * 2002-07-19 2004-01-22 Philippe Becourt Taste masked oral composition of telithromycin
CA2492874C (en) * 2002-07-19 2011-09-20 Aventis Pharma S.A. Taste masked oral composition of telithromycin
CA2529817C (en) * 2003-03-10 2013-02-12 Optimer Pharmaceuticals, Inc. Novel antibacterial agents
US9814657B2 (en) * 2009-04-27 2017-11-14 Premier Dental Products Company Buffered microencapsulated compositions and methods
WO2011112864A1 (en) * 2010-03-10 2011-09-15 Cempra Pharmaceuticals, Inc. Parenteral formulations of macrolide antibiotics
DK2550286T3 (en) * 2010-03-22 2016-02-29 Cempra Pharmaceuticals Inc CRYSTALLINE FORMS OF A MACROLID AND APPLICATIONS THEREOF
US20130164351A1 (en) * 2010-08-30 2013-06-27 Cempra Pharmaceuticals Inc. Methods of treating bacterial infections through pulmonary delivery of fusidic acid
PL2748165T3 (pl) * 2011-08-27 2017-05-31 Wockhardt Limited Pochodne 1,6-diazabicyklo[3,2,1]oktan-7-onu i ich zastosowanie w leczeniu zakażeń bakteryjnych

Also Published As

Publication number Publication date
JP2017523975A (ja) 2017-08-24
ZA201701487B (en) 2021-05-26
AU2015301154A1 (en) 2017-02-23
CA2957034A1 (en) 2016-02-11
EP3185864A1 (en) 2017-07-05
SG11201700827RA (en) 2017-03-30
IL250349A0 (en) 2017-03-30
US20190209530A1 (en) 2019-07-11
CN106604729A (zh) 2017-04-26
WO2016022658A1 (en) 2016-02-11
EP3185864A4 (en) 2018-03-28
RU2017104163A3 (es) 2019-02-15
RU2017104163A (ru) 2018-09-06
US20170224664A1 (en) 2017-08-10
KR20170039689A (ko) 2017-04-11
BR112017002335A2 (pt) 2018-01-16

Similar Documents

Publication Publication Date Title
MX2017001569A (es) Formulaciones de suspención oral en polvo de agentes antibacterianos.
PH12016500868A1 (en) Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children
PH12017550040A1 (en) Compositions for use in the prevention or treatment of gastrointestinal infections/inflammations in infants or young children
MY187540A (en) Compounds active towards bromodomains
NZ733125A (en) Isoquinoline compounds for the treatment of hiv
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
IL270812B1 (en) Solid preparations for oral administration containing semaglutide and dapagliflozin and their use in medicine
IL264232A (en) Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
LT3709978T (lt) Farmacinė geriamoji kompozicija, apimanti bakterijas
NZ745188A (en) 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
NZ745186A (en) 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
WO2016074641A8 (zh) Nadh或其盐在制备治疗苯丙酮尿症药物或保健品的应用
WO2017121646A8 (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
MX2018008643A (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5] -decano.
EP3600305A4 (en) BERBERIN ALKALOID FORMULATIONS FOR THE PREVENTION AND / OR TREATMENT OF INFECTIOUS DISEASES
WO2015130547A8 (en) Bis-cyclic guanidine compound compositions, methods of use and treatment thereof
CA3011003A1 (en) Bacterial ghosts for the treatment of cancer
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12019500092A1 (en) Nutritional compositions for infants and/or young children comprising oligosaccharides
MX2018000092A (es) Nuevo lipolantipeptido biciclico, preparacion y uso como agente antimicrobiano.
MX2018009948A (es) Formulaciones de oritavancina.
MX2017013433A (es) Composiciones antibacterianas.
WO2016072854A3 (en) Pantothenamide analogues
MX2017013434A (es) Composiciones antibacterianas.